Symbols

CLLS

Cellectis·NASDAQ

--(--)

Signals Analysis

Bullish signal 1

Bearish signal 2

MACD Golden Cross

EPS Below Expectations

Consecutive Revenue Decline

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About CLLS

Cellectis S.A.

A biotechnology company that develops immunotherapies and gene-edited allogenic cancer therapies

Industry

Biological Technology

Established Date

01/04/2000

Listing Date

03/25/2015

Exchange

NASDAQ Stock Exchange

Full-time Employees

224

Fiscal Year Ends

12-31

Website

www.cellectis.com

Security Type

Depository Receipts (Ordinary Shares)

Office address

Cellectis S.A. 8 rue de la Croix Jarry 75013 Paris France

Business

Introduction

Cellectis S.A. was established on January 4, 2000. The company is a clinical-stage biotechnology company that leverages their core proprietary technology to develop gene-edited products with a portfolio of allogeneic chimeric antigen receptor T cells, or candidates in the field of immuno-oncology, and gene-edited hematopoietic stem cells and progenitors, or HSPC, candidates for other therapeutic indications.

Company Financials

EPS

CLLS has released its 2025 Q3 earnings. EPS was reported at 0.01, versus the expected -0.23, beating expectations. The chart below visualizes how CLLS has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

CLLS has released its 2025 Q4 earnings report, with revenue of 5.56M, reflecting a YoY change of -25.37%, and net profit of -26.32M, showing a YoY change of -544.41%. The Sankey diagram below clearly presents CLLS's revenue sources and cost distribution.